Get the Stockscreener App
7.07
2.32%
0.16
Upstream Bio Inc stock is traded at $7.07, with a volume of 688.25K.
It is up +2.32% in the last 24 hours and down -0.98% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$6.91
Open:
$6.95
24h Volume:
688.25K
Relative Volume:
1.12
Market Cap:
$387.23M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-2.4363
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
-2.48%
1M Performance:
-0.98%
6M Performance:
-19.20%
1Y Performance:
-62.03%
1-Day Range:
$6.80
$7.14
1-Week Range:
$6.80
$7.70
52-Week Range:
$5.85
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
7.07 | 378.47M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright - MarketBeat
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio, Inc. to drive physician engagement - Traders Union
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - Kalkine
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Why Did UPB Stock Plunge 40% Today? - Stocktwits
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36 - Moomoo
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Upstream Bio Targets Q1 2027 Start for Phase - Minichart
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP - TradingView
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP - Bitget
Pstream Bio stock rises 2.6% after Q2 results and pipeline update - Traders Union
Form 8K Upstream Bio Inc For: 11 August By Investing.com - Investing.com Canada
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary - TradingView
Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash - Stock Titan
Upstream Bio Q2 net loss narrows slightly on lower R&D costs - TradingView
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
Upstream Bio Posts $39.7 Million Q2 Net Loss as Trials Advance - quiverquant.com
Upstream Bio, Inc. sets Phase 3 trial for sever asthma and CRSwNP in Q1 2027 - Traders Union
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress - WBOC TV
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Upstream Bio Inc (UPB) Stock News Today - tradingkey.com
Upstream Bio, Inc. (UPB) Stock Analysis: A Hidden Gem in Biotechnology with a 456% Potential Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB - MarketBeat
BlackRock, Inc. Trims Stake in Upstream Bio Inc (UPB) Amid Clini - GuruFocus
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Upstream Bio (UPB) Gains Ground: Testing Key Resistance Levels After 2.5% AdvanceBox Spread - dars.gov.et
Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Cash Flow - TradingKey
UPB|Upstream Bio Inc|Price:6.780|Chg%:+0.360 - TradingKey
UPB|Upstream Bio Inc|Price:6.400|Chg%:-0.010 - TradingKey
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Balance Sheet - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
UPB|Upstream Bio Inc|Price:7.450|Chg%:+0.200 - TradingKey
Upstream Bio Inc. (UPB) Holds Steady Near Support as Traders Eye Resistance BreakoutHigh Yield Stocks - dars.gov.et
Upstream Bio Inc (UPB) Income Statement - tradingkey.com
Upstream Bio, Inc. Revenue Breakdown – NASDAQ:UPB - TradingView
Hsbc Holdings PLC Makes New $5.76 Million Investment in Upstream Bio, Inc. $UPB - MarketBeat
Decheng Capital LLC Sells 418,210 Shares of Upstream Bio, Inc. $UPB - MarketBeat
SEB Asset Management AB Buys New Stake in Upstream Bio, Inc. $UPB - MarketBeat
Enterprise value to revenue forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
ETFs Investing in Upstream Bio, Inc. Stocks - TradingView
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineEarnings Stability Report - dars.gov.et
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):